What does this research mean for the field?

Achieving high PARP1 selectivity relies on key design strategies such as adenine-pocket engagement, linker optimization, conformational control, and scaffold innovation, though the currently disclosed chemical space remains limited and offers significant opportunities for future therapeutic development. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To review the patent landscape and structural advances in selective PARP1 inhibitors from 2021 to 2025, identifying chemical strategies that improve therapeutic safety.

August 22, 2026Expert Opinion on Therapeutic Patents

Selective PARP1 inhibitors (2021–2025): patent landscape, structural evolution, and future therapeutic opportunities

View Full Paper

Ask AI

Bookmark

To review the patent landscape and structural advances in selective PARP1 inhibitors from 2021 to 2025, identifying chemical strategies that improve therapeutic safety.
Surveyed global patent filings and literature published between 2021 and 2025 concerning selective PARP1 small-molecule inhibitors.
Analyzed structural evolution patterns focusing on AZD5305 derivatives, quinazolinone chemotypes, isoquinolinone chemotypes, and adenine-pocket binding interactions.
Selective PARP1 targeting relies heavily on adenine-pocket engagement, linker remodeling, conformational restriction, and scaffold diversification to minimize nonselective off-target toxicities.
The currently disclosed chemical space remains relatively narrow, demonstrating strong therapeutic and intellectual property opportunities for novel scaffolds with improved safety profiles.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Patent review reveals key structural strategies for selective PARP1 inhibitors, highlighting opportunities to reduce hematological toxicity in targeted cancer therapies.

Cite This Study

Duan et al. (2026) studied this question.

synapsesocial.com/papers/6a895f62ca7ade938187e057 https://doi.org/10.1080/13543776.2026.2722028

View Full Paper

Ask AI

Bookmark

Implication

Patent review reveals key structural strategies for selective PARP1 inhibitors, highlighting opportunities to reduce hematological toxicity in targeted cancer therapies.

Selective PARP1 inhibitors (2021–2025): patent landscape, structural evolution, and future therapeutic opportunities

Key Points

Discussion

Implication

Cite This Study

Selective PARP1 inhibitors (2021–2025): patent landscape, structural evolution, and future therapeutic opportunities

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading